PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23606931-2 2012 The novel human IgG1 CD20 monoclonal antibody ofatumumab has shown significant activity in difficult to treat patients with chronic lymphocytic leukemia, namely those resistant or refractory to fludarabine and alemtuzumab and has now been licensed for this uncommon indication. fludarabine 194-205 keratin 20 Homo sapiens 21-25 33244584-1 2021 OBJECTIVE: Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL). fludarabine 11-22 keratin 20 Homo sapiens 117-121 26489498-2 2015 Rituximab, the most widely used anti-CD20 antibody in routine clinical practice, led not only to improvement of progression-free survival, but also to improvement of overall survival in previously untreated patients with good performance status in combination with fludarabine and cyclophosphamide. fludarabine 265-276 keratin 20 Homo sapiens 37-41 22269114-9 2012 Our data support fludarabine, cyclophosphamide, and rituximab-based nonablative conditioning allo-SCT in CD20(+) B-cell lymphoid malignancies and it is time to compare this regimen with an alternative reduced-intensity conditioning regimen in B-cell malignancies. fludarabine 17-28 keratin 20 Homo sapiens 105-109 21595596-1 2011 Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved for the treatment of chronic lymphocytic leukemia refractory to alemtuzumab and fludarabine. fludarabine 150-161 keratin 20 Homo sapiens 27-31 21856867-1 2011 Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab (FA-ref) and patients refractory to fludarabine with bulky (> 5 cm) lymph nodes (BF-ref). fludarabine 203-214 keratin 20 Homo sapiens 22-26 21918174-1 2011 PURPOSE: Ofatumumab is an anti-CD20 antibody recently approved for treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL); it mediates much stronger complement-dependent cytotoxicity (CDC) than rituximab. fludarabine 80-91 keratin 20 Homo sapiens 31-35 22287865-2 2011 Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved in the US and Europe for the treatment of CLL refractory to alemtuzumab and fludarabine. fludarabine 146-157 keratin 20 Homo sapiens 27-31 21246311-0 2011 Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. fludarabine 25-36 keratin 20 Homo sapiens 146-150 18006839-0 2007 Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. fludarabine 95-106 keratin 20 Homo sapiens 27-31 20194866-0 2010 Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. fludarabine 49-60 keratin 20 Homo sapiens 27-31 20620977-4 2010 The most recent antibody to be approved by regulatory agencies is ofatumumab, a new anti-CD20 antibody, with efficacy in patients whose disease is refractory to both fludarabine and alemtuzumab. fludarabine 166-177 keratin 20 Homo sapiens 89-93 20425394-5 2010 Second-generation monoclonal anti-CD20 antibodies in clinical trials include ofatumumab, which demonstrated activity in fludarabine-refractory patients with bulky lymphadenopathy. fludarabine 120-131 keratin 20 Homo sapiens 34-38 14697987-0 2003 B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen. fludarabine 143-154 keratin 20 Homo sapiens 57-61 16430461-0 2006 Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab. fludarabine 24-35 keratin 20 Homo sapiens 80-84 14697987-8 2003 Notably, lymph node enlargement and CD20+ blood excess occurred significantly more frequently among patients receiving a Fludarabine (Flu) and anti-thymocyte globulin (ATG) conditioning regimen than those whose treatment lacked Flu independent of whether they received ATG (0.80 vs 0.44; P =.036). fludarabine 121-132 keratin 20 Homo sapiens 36-40 14697987-8 2003 Notably, lymph node enlargement and CD20+ blood excess occurred significantly more frequently among patients receiving a Fludarabine (Flu) and anti-thymocyte globulin (ATG) conditioning regimen than those whose treatment lacked Flu independent of whether they received ATG (0.80 vs 0.44; P =.036). fludarabine 121-124 keratin 20 Homo sapiens 36-40 14697987-8 2003 Notably, lymph node enlargement and CD20+ blood excess occurred significantly more frequently among patients receiving a Fludarabine (Flu) and anti-thymocyte globulin (ATG) conditioning regimen than those whose treatment lacked Flu independent of whether they received ATG (0.80 vs 0.44; P =.036). fludarabine 134-137 keratin 20 Homo sapiens 36-40 8599867-8 1996 Phenotypic analysis of the peripheral mononuclear cells in 34 consecutive CLL patients revealed a marked reduction in CD5/CD20 and CD4 cell numbers after three courses of fludarabine with less effect on CD8 and CD56 cells. fludarabine 171-182 keratin 20 Homo sapiens 122-126 12270062-1 2002 In a patient with acute myeloid leukaemia, treated with several courses of chemotherapy including a fludarabine-containing regimen, severe symptoms due to Epstein-Barr virus reactivation occurred but could be successfully treated with the monoclonal anti-CD20 antibody rituximab. fludarabine 100-111 keratin 20 Homo sapiens 255-259 10444162-2 1999 Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use. fludarabine 127-138 keratin 20 Homo sapiens 172-176 10529513-1 1999 Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab), a 31-year-old woman with B-prolymphocytic leukemia, who had been resistant to CHOP, fludarabine, pentostatin and 2-CdA, achieved complete remission. fludarabine 179-190 keratin 20 Homo sapiens 47-51